First, we stratified the patients into eight SLE sub-phenotype groups, including SLE patients who were positive for anti-SSA/B, anti-Sm, anti-RNP, or anti-dsDNA antibodies, or who had low complement levels, nephritis or neurological disorders. This evidence concerns the gene RNPC3 and systemic lupus erythematosus.